Related Experiment Videos
Bone-marrow transplantation for metachromatic leucodystrophy
Lancet (London, England)
|August 31, 1985
Insights
Bone marrow transplant (BMT) showed promise for treating a child with metachromatic leukodystrophy. Donor cells in cerebrospinal fluid and continued development suggest BMT
Area of Science:
- Neurology
- Hematology
- Genetics
Background:
- Late infantile metachromatic leukodystrophy is a rare genetic disorder affecting the central nervous system.
- Bone marrow transplantation (BMT) is a potential therapeutic option for certain inherited metabolic diseases.
Observation:
- An 11-month-old boy diagnosed with metachromatic leukodystrophy received a bone marrow transplant from an HLA-identical sibling.
- Cerebrospinal fluid analysis 6 months post-transplant revealed exclusively donor-derived leukocytes.
Findings:
- The patient demonstrated sustained developmental progress 33 months after the bone marrow transplant.
- Successful engraftment of donor cells in the central nervous system was confirmed.
Implications:
- Bone marrow transplantation may be an effective treatment strategy for specific congenital metabolic disorders impacting the central nervous system.
- This case highlights the potential of BMT in managing neurodegenerative genetic conditions.
Abstract:
An 11-month-old boy with late infantile metachromatic leucodystrophy was given a bone-marrow transplant (BMT) from an HLA-identical sister; 6 months later his cerebrospinal fluid leucocytes were exclusively of donor origin. Coupled with the patient's continued developmental progress, as assessed 33 months after the procedure, the findings suggest that BMT may be an effective treatment for some congenital metabolic disorders which affect the central nervous system.